Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

Developing and utilizing controlled human models of infection.

Porter CK, Louis Bourgeois A, Frenck RW, Prouty M, Maier N, Riddle MS.

Vaccine. 2017 Jun 2. pii: S0264-410X(17)30727-2. doi: 10.1016/j.vaccine.2017.05.068. [Epub ahead of print]

PMID:
28583306
2.

Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.

Klein NP, Abu-Elyazeed R, Cornish M, Leonardi ML, Weiner LB, Silas PE, Grogg SE, Varman M, Frenck RW, Cheuvart B, Baine Y, Miller JM, Leyssen M, Mesaros N, Roy-Ghanta S.

Vaccine. 2017 Jun 16;35(28):3564-3574. doi: 10.1016/j.vaccine.2017.05.018. Epub 2017 May 20.

3.

Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.

Frenck RW Jr, Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, Sebastian S, Nanra J, Jansen KU, Gruber WC, Anderson AS, Girgenti D.

Vaccine. 2017 Jan 5;35(2):375-384. doi: 10.1016/j.vaccine.2016.11.010. Epub 2016 Dec 1.

4.

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

Creech CB, Frenck RW Jr, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.

Vaccine. 2017 Jan 5;35(2):385-394. doi: 10.1016/j.vaccine.2016.11.032. Epub 2016 Nov 17.

5.
6.

Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.

Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B; B1851020 Study Group.

Vaccine. 2016 Jun 24;34(30):3454-62. doi: 10.1016/j.vaccine.2016.04.093. Epub 2016 May 5.

PMID:
27155493
7.

Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropenia.

Hahn A, Fukuda T, Hahn D, Mizuno T, Frenck RW Jr, Vinks AA.

Pharmacogenomics. 2016 Apr;17(6):547-59. doi: 10.2217/pgs-2015-0008. Epub 2016 Apr 5.

8.

Melody Valve Bartonella henselae Endocarditis in an Afebrile Teen: A Case Report.

Sosa T, Goldstein B, Cnota J, Bryant R, Frenck R, Washam M, Madsen N.

Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-1548. Epub 2015 Dec 11.

9.

A cross-sectional household cluster serosurvey of hepatitis C virus antibodies in an urban slum of Cairo, Egypt in 2004.

Nakhla IA, Sanders JW, Mohareb EW, Samy S, Cosby MT, Mostafa MM, Riddle MS, Frenck RW Jr.

Trop Dis Travel Med Vaccines. 2015 Oct 1;1:9. doi: 10.1186/s40794-015-0012-7. eCollection 2015.

10.

Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.

Hahn A, Frenck RW Jr, Allen-Staat M, Zou Y, Vinks AA.

Ther Drug Monit. 2015 Oct;37(5):619-25. doi: 10.1097/FTD.0000000000000190.

11.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

Bryant KA, Frenck R, Gurtman A, Rubino J, Treanor J, Thompson A, Jones TR, Sundaraiyer V, Baxter LM, Gruber WC, Emini EA, Scott DA, Schmoele-Thoma B.

Vaccine. 2015 Oct 26;33(43):5854-60. doi: 10.1016/j.vaccine.2015.08.080. Epub 2015 Sep 9.

PMID:
26362099
12.

Serological Correlates of Protection against a GII.4 Norovirus.

Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinjé J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowski A, Baehner F, Goodwin R, Edmonds A, Mendelman PM.

Clin Vaccine Immunol. 2015 Aug;22(8):923-9. doi: 10.1128/CVI.00196-15. Epub 2015 Jun 3.

13.

Validation of a pediatric population pharmacokinetic model for vancomycin.

Hahn A, Frenck RW Jr, Zou Y, Vinks AA.

Ther Drug Monit. 2015 Jun;37(3):413-6. doi: 10.1097/FTD.0000000000000153.

14.

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR; DMID 13-0032 H7N9 Vaccine Study Group.

JAMA. 2014 Oct 8;312(14):1409-19. doi: 10.1001/jama.2014.12854.

PMID:
25291577
15.

Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinjé J, Gregoricus N, Frenck RW Jr, Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM.

J Infect Dis. 2015 Mar 15;211(6):870-8. doi: 10.1093/infdis/jiu497. Epub 2014 Sep 9.

PMID:
25210140
16.

The epidemiological and clinical characteristics of diarrhea associated with enteropathogenic, enteroaggregative and diffuse-adherent Escherichia coli in Egyptian children.

Ahmed SF, Shaheen HI, Abdel-Messih IA, Mostafa M, Putnam SD, Kamal KA, Sayed AN, Frenck RW Jr, Sanders JW, Klena JD, Wierzba TF.

J Trop Pediatr. 2014 Oct;60(5):397-400. doi: 10.1093/tropej/fmu034. Epub 2014 Aug 13.

PMID:
25122630
17.

Diarrhea burden due to natural infection with enterotoxigenic Escherichia coli in a birth cohort in a rural Egyptian community.

Mansour A, Shaheen HI, Amine M, Hassan K, Sanders JW, Riddle MS, Armstrong AW, Svennerholm AM, Sebeny PJ, Klena JD, Young SY, Frenck RW.

J Clin Microbiol. 2014 Jul;52(7):2595-603. doi: 10.1128/JCM.00215-14. Epub 2014 May 14.

18.

Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.

Callahan ST, Wolff M, Hill HR, Edwards KM; NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group.

J Infect Dis. 2014 Oct 15;210(8):1270-4. doi: 10.1093/infdis/jiu245. Epub 2014 May 1.

19.

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5.

PMID:
24606865
20.

Pathogenicity and phenotypic characterization of enterotoxigenic Escherichia coli isolates from a birth cohort of children in rural Egypt.

Mansour A, Shaheen HI, Amine M, Hassan K, Sanders JW, Riddle MS, Armstrong AW, Svennerholm AM, Sebeny PJ, Klena JD, Young SY, Frenck RW Jr.

J Clin Microbiol. 2014 Feb;52(2):587-91. doi: 10.1128/JCM.01639-13. Epub 2013 Dec 11.

Supplemental Content

Loading ...
Support Center